Cargando…
核酸干扰药物在抗肿瘤领域的机遇和挑战
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeu...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346155/ https://www.ncbi.nlm.nih.gov/pubmed/35899445 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.102.20 |
Ejemplares similares
-
浅析MIDD在抗肿瘤药物临床研究中的应用
Publicado: (2022) -
抗肿瘤药物警戒研究进展
Publicado: (2022) -
境外授权许可引进抗肿瘤新药临床研发策略的审评考虑
Publicado: (2022) -
抗体偶联药物在肺癌中的研究进展与展望
Publicado: (2022) -
研究者发起的临床研究用于支持新药研发面临的挑战
Publicado: (2022)